Exploring Strategic Partnerships to Expand Platform Beyond Reproductive HealthSAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 million non-dilutive funding installment under its multi-year grant agreement to support development of DARE-LARC1, the contraception-focused use case of Daré’s intelligent drug delivery system (DARE-IDDS ...

SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803 Webcast: Participants can use the ...

Core Insights - Cerevance is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and obesity, with presentations scheduled at the Alzheimer's Association International Conference (AAIC) 2025 [1] Group 1: Upcoming Presentations - Cerevance will present a Phase 1 study on CVN293, an investigational inhibitor targeting NLRP3-mediated neuroinflammation, on July 28, 2025 [2] - Another presentation will focus on the NETSseq platform, revealing insights into astrocyte function in Alzheimer's disease, scheduled for July 30, 2025 [2] Group 2: NETSseq Platform - The NETSseq platform allows for the identification of subtle molecular changes driving disease progression by analyzing brain tissue from over 20,000 donors aged 8 to 104 [3] - This platform aids in identifying low-level expressed targets and rare cell types, enhancing the understanding of neurodegenerative diseases [3] Group 3: CVN293 Overview - CVN293 is a selective oral inhibitor of KCNK13, aimed at reducing neuroinflammation and potentially modifying disease progression in neurodegenerative disorders [4] - The mechanism of CVN293 may also provide therapeutic benefits for obesity, identified through the NETSseq platform [4] Group 4: Company Pipeline - Cerevance's lead investigational treatment, solengepras, is in Phase 3 development for Parkinson's disease, while CVN766 targets binge eating disorder and schizophrenia [5] - CVN293 represents a novel intervention point for both neurodegenerative disorders and obesity [5]

BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) recommend that stockholders vote FOR the issuance of shares in connection with the previously disclosed proposed merger with Inmagene Biopharmaceuticals (“Inmagene”) at Ikena’s upcoming Annual Meeting of Stockholders on July 15, 2025. ISS and Glass Lewis are leading U.S. institutional voting advisory ...

Core Viewpoint - Helix Acquisition Corp. II is set to hold an extraordinary general meeting on August 4, 2025, to discuss the business combination with TheRas, Inc. (BridgeBio Oncology Therapeutics), following the SEC's declaration of the registration statement as effective [1][2][3]. Company Overview - Helix Acquisition Corp. II is a special purpose acquisition company (SPAC) that raised $184 million in its initial public offering on February 9, 2024, and is sponsored by Cormorant Asset Management [5]. - TheRas, Inc. (BridgeBio Oncology Therapeutics) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies [4]. Business Combination Details - The business combination agreement was finalized on February 28, 2025, and is subject to various conditions before closing [6]. - Upon completion of the transaction, the company will be renamed "BridgeBio Oncology Therapeutics" [6]. - The proxy statement/prospectus will be mailed to Helix's shareholders of record as of June 30, 2025, for their consideration [2][6].

Core Insights - Zevra Therapeutics, Inc. announced presentations on MIPLYFFA (arimoclomol) at the NNPDF Conference, highlighting its role as the first FDA-approved treatment for Niemann-Pick disease type C (NPC) [1][2] - MIPLYFFA is indicated for use in combination with miglustat for treating neurological manifestations of NPC in patients aged 2 years and older [7][6] Presentation and Research Findings - Dr. Barbara K. Burton presented an overview of MIPLYFFA, emphasizing its unique mechanism that improves lysosomal function and halts disease progression at 12 months in a pivotal study [2][3] - The pivotal trial demonstrated that arimoclomol combined with miglustat halted disease progression compared to placebo, confirmed by a 48-month open-label extension study [4][6] - Two posters were presented: one detailing long-term effectiveness and safety of arimoclomol, and another providing mechanistic evidence of arimoclomol's action through the CLEAR network [4][5] Drug Mechanism and Clinical Significance - MIPLYFFA enhances the activation of transcription factors TFEB and TFE3, leading to the upregulation of CLEAR genes and improved lysosomal function [6][17] - The drug has shown to reduce unesterified cholesterol in NPC fibroblasts, although the clinical significance of this finding remains to be fully understood [6] Company Overview - Zevra Therapeutics focuses on developing therapies for rare diseases with limited treatment options, aiming to create transformational therapies through data-driven strategies [18]

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature’s Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment wi ...

We are talking to industry constantly to figure out how we can be helpful. Which of their products being proposed are in line with our national priorities. That is meeting a large unmet public health need.Domesticating manufacturing as a national security issue. Increasing the affordability of drugs, which is an access problem. This president does not like to see Americans getting ripped off.And we've been paying more for drugs than in many wealthy countries around the world. Can you do anything about that. ...

MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the “Series A Warrants”) and accompanying Series B warrants to purchase common shares (the “Series B Warrants”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives.Let's consider two stocks that have significantly lagged the market in recent years but could still fall further: Canopy Growth (CGC -5.95%) and Novavax (NVAX 0.92%). 1. Canopy GrowthCanopy Growth emerged as a leader in the cannabis industry toward the end o ...